null

“Inflammatory mediator synthesis enzymes” refers to a class of enzymes responsible for producing bioactive molecules that drive and regulate the inflammatory response, including cyclooxygenases (COX-1, COX-2), lipoxygenases (LOX variants), cytochrome P450 monooxygenases (CYPs), phospholipase A2 (PLA2), and various proteases. These enzymes convert arachidonic acid and other substrates into prostaglandins, leukotrienes, thromboxanes, and specialized pro-resolving mediators, which orchestrate signaling events in the immune and inflammatory response. They are central to the pathology of inflammatory diseases, and are major therapeutic targets for anti-inflammatory drugs and immunomodulators. However, targeting these enzymes can disrupt both pathological and physiological processes, necessitating care in drug design and application. Because the term is generic and encompasses many different proteins, "inflammatory mediator synthesis enzymes" should be replaced with a specific enzyme name (e.g., "Cyclooxygenase-2," "Arachidonate 5-lipoxygenase") for precise research, therapeutic, or biomarker usage.

Other names

Eicosanoid-synthesizing enzymesMediator biosynthetic enzymesInflammatory pathway enzymesProinflammatory enzyme familiesArachidonic acid metabolizing enzymes

Inhibition of mediator synthesis (by blocking COX, LOX, PLA2, or CYP enzymes); Antagonism of mediator receptors (e.g., CysLT1 antagonists); Suppression of enzyme transcription (e.g., via cytokine modulation with steroids); Modulation of enzyme activity (some drugs stabilize or activate anti-inflammatory enzymes, e.g., resolving enzyme pathways)